• Three new patient cases demonstrating SCENESSE efficacy in vitiligo
• Significant repigmentation observed in patients with long-standing disease
• No unexpected safety concerns identified

Clinuvel Pharmaceuticals has presented new case studies at the European Academy of Dermatology and Venereology (EADV) conference demonstrating the efficacy of its drug SCENESSE (afamelanotide 16mg) in treating vitiligo patients. The three patients, with Fitzpatrick skin types IV and V and long-standing disease, were treated at a single reference hospital in La Reunion, France, as part of Clinuvel's ongoing CUV105 study. The patients received seven SCENESSE implants and up to 40 narrowband ultraviolet B (NB-UVB) phototherapy sessions. At the first follow-up visit, 14 weeks after completion of treatment, the principal physician evaluated the cases and reported significant and stable repigmentation in the affected areas, including the face, forehead, perioral region, and groin. One patient had previously been resistant to topical treatments, while another had experienced relapse following partial treatment response. No unexpected safety concerns were identified. Clinuvel's Director of Global Clinical Affairs, Dr. Emilie Rodenburger, commented that the results are satisfying, as the patients are receiving benefit from the treatment, and the treating physicians are excited to have a therapy that works for patients with extensive vitiligo.